Breaking News
Get 45% Off 0
🚨 Don’t miss your updated list of AI-picked stocks for this month
Pick Stocks with AI

Medidata's Payment Solution To Make Reimbursements Easy

By Zacks Investment ResearchStock MarketsJul 19, 2016 07:03AM ET
www.investing.com/analysis/tratan-de-consolidar-niveles-tras-los-recientes-r%C3%A9cords-y-cuatro-semanas-200142686
Medidata's Payment Solution To Make Reimbursements Easy
By Zacks Investment Research   |  Jul 19, 2016 07:03AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
MDSO_...
0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
OMCL
-1.07%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
FMI
0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
NVTAQ
0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Medidata Solutions Inc (NASDAQ:MDSO) recently introduced Medidata Payments, a cloud-based payment technology and an add-on to the company’s’ leading Medidata Clinical Cloud.

With this launch, the company is set to simplify the reimbursement procedure in the space of clinical research by addressing all the probable challenges like erroneous calculations along with inaccurate and delayed payments.

Medidata Payments offers a precise payment solution, unifying pre-payments, holdbacks, divide payments among different payees, payments in multiple currencies and accruals. The platform also provides clinical trial sponsors with easy solutions that identifies and calculates withholding-tax, captures indirect tax and performs worldwide disimbursement.

The Payment solution works in three major steps -- managing of contract requirements, recording the costs generated by the trial data and disbursing payments to the investigative sites across multiple clinical researches worldwide.

MEDIDATA SOLUTN Price and Consensus

MEDIDATA SOLUTN Price and Consensus | MEDIDATA SOLUTN Quote

Medidata’s new launch is likely to revolutionize the clinical trial payment platform, fortifying partnerships between sponsors, contract research organizations and clinical investigation sites. The tool is also likely to be beneficial to the sponsors who conduct multiple trials globally using more than 125 different currencies.

Notably, Medidata Solutions has 17 out of the top 25 global Pharma companies as enterprise customers, demonstrating its accomplishments in the space. Medidata Payments is likely to fortify the company’s position as it will streamline trial processes to a considerable extent.

Zacks Rank & Key Picks

Currently, Medidata Solutions has a Zacks Rank #3 (Hold).

Better-ranked stocks in the medical instrument sector include Foundation Medicine Inc. (NASDAQ:FMI) , Omnicell Inc (NASDAQ:OMCL) and Invitae Corporation (NYSE:NVTA) . While Foundation Medicine and Omnicell sport a Zacks Rank #1 (Strong Buy), Invitae Corporation holds a Zacks Rank #2 (Buy).



OMNICELL INC (OMCL): Free Stock Analysis Report

MEDIDATA SOLUTN (MDSO): Free Stock Analysis Report

FOUNDATION MED (FMI): Free Stock Analysis Report

INVITAE CORP (NVTA): Free Stock Analysis Report

Original post

Zacks Investment Research

Medidata's Payment Solution To Make Reimbursements Easy
 

Related Articles

Medidata's Payment Solution To Make Reimbursements Easy

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email